Overview

Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

Status:
Unknown status
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Duloxetine (Cymbalta®) is an effective treatment in reducing the symptoms of Posttraumatic Stress Disorder (PTSD).
Phase:
Phase 3
Details
Lead Sponsor:
Canive, Jose M., M.D.
Collaborator:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride